1292836-05-5

Basic information

• Product Name: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate
• Synonyms: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate;N-[(1S)-1-[[(2S)-2-(5-Bromo-1H-imidazol-2-yl)-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamic acid methyl ester;EOS-61044;methyl ((S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate(WXG03511)
• CAS NO: 1292836-05-5
• Molecular Formula: C₁₄H₂₁BrN₄O₃
• Molecular Weight: 373.24554
• Mol File: 1292836-05-5.mol

Chemical Properties

• Boiling Point: 609.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.443±0.06 g/cm3(Predicted)
• PKA: 11.13±0.10(Predicted)
• CAS DataBase Reference: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate(1292836-05-5)
• EPA Substance Registry System: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate(1292836-05-5)

Safety Data

• Hazardous Substances Data: 1292836-05-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate is used as a key intermediate in the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure allows for the development of new drugs with therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate serves as a valuable building block for the design and synthesis of novel drug candidates. Its unique structural features enable researchers to explore its potential in the development of new therapeutic agents.
Used in Drug Discovery:
Methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate is used in drug discovery processes to identify new lead compounds with potential therapeutic properties. Its unique structure and functional groups make it a promising candidate for further research and development.
Used in Chemical Synthesis Industry:
In the chemical synthesis industry, methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate is used as a versatile building block for the creation of various complex organic molecules. Its unique structure and functional groups provide opportunities for the development of new synthetic routes and methodologies.

Upstream product

• 1240893-76-8 (S)-2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1007882-59-8 (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1007882-58-7 (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 72-18-4 L-valine 
• 1258253-82-5 (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 69610-41-9 Boc-L-Pro-H 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 1007882-59-8 (S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1258234-18-2 (S)-5-bromo-2-(pyrrolidin-2-yl)-1H-imidazole hydrochloride 

Downstream Products

• 1370647-84-9 C₅₂H₆₁N₉O₈ 
• 1370647-67-8 C₅₂H₅₇N₉O₈ 
• 1370468-36-2 N,N'-[[(6S)-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl-[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis[carbamic acid] C,C'-dimethyl ester 
• 1613081-64-3 dimethyl((2S,2’S)-((2S,2’S)-2,2’-(5,5’-((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3methyl-1oxobutane-2,1-diyl))dicarbamate 
• 1620546-33-9 C₄₂H₅₂FN₉O₇ 
• 1613081-63-2 C₅₂H₅₄F₂N₁₀O₇S 
• 1620546-02-2 C₃₈H₃₃ClF₂N₆O₄S 
• 1620545-45-0 C₅₂H₆₁FN₁₀O₇S 
• 1620546-33-9 C₄₂H₅₂FN₉O₇ 
• 1620544-87-7 C₅₂H₅₄F₂N₁₀O₇S 
• 1620546-02-2 C₃₈H₃₃ClF₂N₆O₄S 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF

The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.